MorphoSys AG ADR Valuation
Based on Macroaxis valuation methodology, the firm cannot be evaluated at this time. MorphoSys AG ADR last-minute Real Value cannot be determined due to lack of data. The latest price of MorphoSys AG ADR is $0.0. Our model forecasts the value of MorphoSys AG ADR from analyzing the firm fundamentals such as Profit Margin of (1.91) %, return on equity of -1.84, and Current Valuation of 2.68 B as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that MorphoSys' price fluctuation is out of control at this time. Calculation of the real value of MorphoSys AG ADR is based on 3 months time horizon. Increasing MorphoSys' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the MorphoSys stock is determined by what a typical buyer is willing to pay for full or partial control of MorphoSys AG ADR. Since MorphoSys is currently traded on the exchange, buyers and sellers on that exchange determine the market value of MorphoSys Stock. However, MorphoSys' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0 | Real 0.0 | Hype 0.0 |
The intrinsic value of MorphoSys' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence MorphoSys' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of MorphoSys AG ADR helps investors to forecast how MorphoSys stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of MorphoSys more accurately as focusing exclusively on MorphoSys' fundamentals will not take into account other important factors: MorphoSys Total Value Analysis
MorphoSys AG ADR is now estimated to have company total value of 2.68 B with market capitalization of 2.86 B, debt of 635.93 M, and cash on hands of 726.83 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the MorphoSys fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.68 B | 2.86 B | 635.93 M | 726.83 M |
MorphoSys Investor Information
The company recorded a loss per share of 1.5. MorphoSys AG ADR had not issued any dividends in recent years. Based on the key indicators related to MorphoSys' liquidity, profitability, solvency, and operating efficiency, MorphoSys AG ADR is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.MorphoSys Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. MorphoSys has an asset utilization ratio of 11.76 percent. This connotes that the Company is making $0.12 for each dollar of assets. An increasing asset utilization means that MorphoSys AG ADR is more efficient with each dollar of assets it utilizes for everyday operations.MorphoSys Ownership Allocation
MorphoSys AG ADR maintains a total of 150.65 Million outstanding shares. Roughly 92.56 % of MorphoSys outstanding shares are held by general public with 7.44 % by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.MorphoSys Profitability Analysis
The company reported the last year's revenue of 238.28 M. Reported Net Loss for the year was (189.73 M) with profit before taxes, overhead, and interest of 229.65 M.About MorphoSys Valuation
The delisted stock valuation mechanism determines MorphoSys' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of MorphoSys AG ADR based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of MorphoSys. We calculate exposure to MorphoSys's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of MorphoSys's related companies.MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. The company was founded in 1992 and is headquartered in Planegg, Germany. Morphosys operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 648 people.
MorphoSys Growth Indicators
Investing in growth stocks can be very risky. If the company such as MorphoSys does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 137.3 M | |
| Quarterly Earnings Growth Y O Y | -0.874 | |
| Forward Price Earnings | 322.5806 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in MorphoSys Stock
If you are still planning to invest in MorphoSys AG ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MorphoSys' history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |